Panmure Gordon (UK) Limited, an exempt principal trader, has disclosed its dealings in the securities of Allergy Therapeutics plc. On August 21, 2023, Panmure Gordon purchased 0.1p ordinary shares of Allergy Therapeutics plc. No sales were made on this date. The highest and lowest price per unit paid/received for the shares was 0.0256.

No cash-settled derivative transactions or stock-settled derivative transactions were reported. Additionally, there were no indemnity or option arrangements, agreements, or understandings related to relevant securities.

This disclosure is made in accordance with Rule 8 of the Takeover Code.